Destiny Pharma plc (“Destiny Pharma” or “the Company”) Data on the antimicrobial activity of XF-73 against bacteria within biofilms to be presented at prestigious 2022 ECCMID Congress Brighton, United Kingdom – […]
Monday March 28, 2022
Result of General Meeting and Total Voting Rights
THIS ANNOUNCEMENT (INCLUDING THE APPENDIX) AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO […]
Friday March 25, 2022
Destiny’s microbiome project article published in Vantage
Destiny Pharma’s CEO, Neil Clark, discusses the Company’s microbiome project with Vantage. Read the full article here
Friday March 25, 2022
Result of Open Offer
THIS ANNOUNCEMENT (INCLUDING THE APPENDIX) AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO […]
Wednesday March 23, 2022
Destiny Pharma publish in the European Biopharmaceutical Review Journal “Global Ri...
Dr Bill Love, Chief Scientific Officer at Destiny Pharma, writes “The rise of antimicrobial resistance (AMR) has necessitated ongoing initiatives to offset the global threat and promote innovation, with financial […]
Tuesday March 22, 2022
Exercise of Options and Total Voting Rights
Destiny Pharma plc (“Destiny Pharma” or “the Company”) Exercise of Options and Total Voting Rights Brighton, United Kingdom – 22 March 2022 – Destiny Pharma (AIM: DEST), a clinical stage […]
Thursday March 17, 2022
Open Offer Application Form
Open Offer Application Form
Thursday March 17, 2022
Form of Proxy
17 March 2022 – Form of Proxy
Wednesday March 9, 2022
Circular to shareholders
09 March 2022 – Circular to shareholders
Tuesday March 8, 2022
Fundraising
THIS ANNOUNCEMENT (INCLUDING THE APPENDICES) (THIS “ANNOUNCEMENT”) AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, […]